StockNews.AISignal intelligence
Kura Oncology, Inc. · NASDAQ · Healthcare
Browse public KURA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Kura Oncology announced promising preliminary results from the FIT-001 trial showing 44% objective response rate and 94% disease control rate for darlifarnib in cabozantinib-pretreated ccRCC patients. This has significant implications for KURA, highlighting potential for overcoming drug resistance and increasing investment interest.
View signal analysisKura Oncology's drug received FDA approval for treating a rare blood cancer. This approval marks a significant achievement for Kura amid ongoing therapy challenges.
View signal analysisKURA's Phase 2 trial for ziftomenib shows significant complete response rates. The benefit-risk profile of ziftomenib remains highly encouraging. KURA aims for FDA NDA submission in Q2 2025 based on positive trial data. Upcoming Phase 3 trials to start in late 2025 evaluate ziftomenib in AML. KURA's partnership with Kyowa Kirin includes $330 million upfront and potential future milestones.
View signal analysisKura Oncology ends takeover talks after a leukemia drug deal. Kura stock plummeted following the announcement of the drug deal.
View signal analysis